Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 7Not yet recruiting 3Recruiting 2Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Ganglioneuroblastoma 1

Interventions

pembrolizumab 68Cyclophosphamide 46Cisplatin 43Nivolumab 36Paclitaxel 33Carboplatin 31Radiotherapy 29Gemcitabine 28Docetaxel 25Dexamethasone 22atezolizumab 21Bevacizumab 20Doxorubicin 19Magnetic Resonance Spectroscopy 18Blood Specimen Collection 18Radiosurgery 17fludarabine 16Vincristine 16Lenalidomide 16Etoposide 16Letrozole 15Ipilimumab 15Fluorouracil 15palbociclib 14Surveys and Questionnaires 14Rituximab 14Radiation 14Leucovorin 14Cytarabine 14durvalumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Colony-Stimulating Factors × 90 days × Clear all
NCT03786783 2026-06-02

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡